“Impressive” results of a new approach to relapsed or refractory Hodgkin lymphoma

By /

Phase 2 study finds that a new treatment combination may improve outcomes for people with relapsed or refractory Hodgkin lymphoma.

A recent, phase 2 study in China has investigated a new treatment combination for classical Hodgkin lymphoma that has come back (relapsed) or not responded (refractory) after previous treatment.

In this study, people with relapsed or refractory classical Hodgkin lymphoma who had had at least two previous treatments were given:

  • camrelizumab on its own or
  • cambrelizumab plus decitabine.

Camrelizumab is a ‘checkpoint inhibitor’ that stops lymphoma cells hiding from your immune system. This allows your immune system to recognise and destroy the lymphoma cells. Some checkpoint inhibitors, such as nivolumab and pembrolizumab, are already available to treat certain people with relapsed or refractory Hodgkin lymphoma.

Decitabine is a chemotherapy drug that works by turning on genes that stop cancer cells growing and dividing. Scientists think it might also boost your immune system’s response to treatment with checkpoint inhibitors. It is currently used to treat people with acute myeloid leukaemia who are not suitable for standard therapy.

In this study, people who were treated with camrelizumab plus decitabine had a much higher response to treatment than people treated with camrelizumab on its own. The response also seemed to last longer in people who received camerlizumab plus decitabine, although longer-term results are needed to confirm this.

These results show that drugs that alters gene activation in this way (called ‘epigenetic modulators’) have the potential to boost the anti-lymphoma response to checkpoint inhibitors. This is a promising new approach that could improve outcomes for people with relapsed or refractory Hodgkin lymphoma.

The authors concluded that adding decitabine to camrelizumab was safe and had an ‘impressively high complete response rate’. Large-scale trials are planned to investigate the treatment further.

To find out more about how clinical trials are used to study new treatments for lymphoma, or to search for a trial that might be suitable for you, visit LIPA clinical trials link.

 

Source: lymphoma-action.org.uk

 

54 thoughts on ““Impressive” results of a new approach to relapsed or refractory Hodgkin lymphoma”

  1. Pingback: cialis at walmart

  2. Pingback: cialis generic

  48. marjack bet

    Very great post. I simply stumbled upon your blog and wanted to mention that
    I have truly loved surfing around your weblog posts.
    In any case I’ll be subscribing for your rss feed and I hope you write
    again soon!

    Reply
  51. spinbet

    Hi, I do think this is a great site. I stumbledupon it 😉 I’m going to return once again since i have book marked it. Money and freedom is the greatest way to change, may you be rich and continue to help other people.

    Reply
  53. CH加密中心学院

    一个高效的学习路径：用Cryptify Hub的导航站找到某个工具的官网 → 自己去阅读文档和教程 → 在实践中遇到问题 → 回到Cryptify Hub的社群里提问或搜索历史讨论。这个路径结合了“官方信息”和“民间经验”，比单纯依赖社群或单纯自学都更有效。但请始终把官方文档作为第一信源，社群经验作为补充参考。民间社群的讨论可能有错误或过时。

    Reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top